Research Paper

A holistic framework for prevention, early diagnosis, and management of cardiovascular diseases

Dr. Omar Qahtan Yaseen*
*Biotechnology, Ministry of Education, Hit, Anbar 31007, Iraq.

Article Info

Article History:
Received: 16 November 2025
Revised: 24 January 2026
Accepted: 01 February 2026
Published: 17 March 2026

Keywords:
Holistic Cardiac Management
Early Diagnosis
Risk Stratification
Digital Health
AI-Assisted Cardiology

ABSTRACT

Background: Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, accounting for 17.9 million deaths annually. Despite advances in pharmaceutical and interventional cardiology, CVD incidence continues to rise, particularly in low- and middle-income countries. Fragmented care models emphasizing acute treatment over prevention and early diagnosis have proven inadequate in curbing this trend.
Objective: To propose and evaluate an integrated, multi-domain framework for the prevention, early diagnosis, and holistic management of CVD, incorporating biomedical, behavioral, technological, and socio-environmental determinants of cardiovascular health.
Methods: A systematic literature review was conducted across PubMed, Embase, Cochrane Library, and Scopus for studies published between 2010 and 2024. A mixed-methods synthesis integrated quantitative data from randomized controlled trials and cohort studies with qualitative patient-reported outcomes. Multi-disciplinary intervention programs, AI-enhanced diagnostic modalities, and risk stratification tools were evaluated.
Results: The integrated model outperformed conventional single-domain approaches, achieving a 42–58% reduction in CVD events and a 32–44% reduction in CVD-related mortality. Digital health interventions improved treatment adherence by 76–88%, while AI-based risk prediction demonstrated 88–94% sensitivity. The framework spans three levels of care: primary prevention through lifestyle modification, secondary prevention through biomarker- and imaging-based screening, and tertiary management through individualized, guideline-based pharmacotherapy combined with cardiac rehabilitation.
Conclusion: This integrative framework, unifying prevention, precision diagnostics, and personalized management, represents a promising strategy for reducing the global CVD burden. Implementation in resource-variable settings requires scalable digital health integration, community engagement, and sustained policy-level commitment.

Corresponding Author:
Dr. Omar Qahtan Yaseen

Journal of Prevention, Diagnosis and Management of Human Diseases (JPDMHD)

Biotechnology, Ministry of Education, Hit, Anbar 31007, Iraq.
Email: omerkahtan@gmail.com

Copyright © 2025 The Author(s). This is an open access article distributed under the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

The cardiovascular diseases (CVDs) represent the greatest non-communicable disease burden in the world as they cause almost a third of all deaths in the world [1]. According to the statistics of the World Health Organization (WHO), the number of people who die of CVDs annually is 17.9 million, of which most of the deaths occur as a result of ischemic heart disease as well as stroke [2]. Regardless of the tremendous advancement in the pharmacological management and invasive interventional procedures, worldwide occurrence of CVD is increasing at a rate that is precipitated by demographic aging, urbanization and lifestyle changes, coupled with poor healthcare facilities within the low- and middle-income countries (LMICs) [3].

The flaws of the current biomedical paradigm - whereby the majority of its applications revolve around management of acute events - have grown more evident. A disease-centric and reactive approach overlooks the multifactorial and complex etiology of CVDs, which is comprised of genetic predispositions, metabolic derangements, behavioral determinants, psychosocial stressors, and environmental exposures [4]. Over 80 percent of the number of premature deaths that occur due to CVD are globally preventable by modification of the major risk factors yet substantial proportions of the at-risk groups are not diagnosed or not adequately treated [5].

The introduction of precision medicine, digital health technologies, artificial intelligence (AI) and evidence-based preventive cardiology provide the most significant opportunities to radically change the paradigms of CVD care [6]. Continuous cardiovascular surveillance and clinical decision support can be ensured by wearable biosensors, the use of machine learning to conduct risk prediction algorithms, remote patient monitoring platforms, and mobile health (mHealth) applications [7]. Such technological advances, with their integration into a systematic, comprehensive framework, will be able to address the gaps in the current prevention, early detection, and chronic disease management [8].

The holistic model suggested by this paper combines three areas of interdependence: (i) primordial and primary prevention which involves population-level and individual risk factors change; (ii) early and accurate diagnosis with multi-modal biomarkers and AI-assisted imaging; and (iii) comprehensive management with personalized pharmacotherapy, cardiac rehabilitation, and technology-based self-management support [9]. The framework is aimed to be flexible in different healthcare settings whether tertiary academic medical centers or in community-based primary care institutions operating in resource-constrained areas [10].

The main purpose of this work is to synthesize the existing evidence in favor of every element of this holistic approach systematically and introduce an integrated patterns of work that can be followed by the healthcare systems and policymakers and clinicians in order to significantly decrease the morbidity and mortality rates caused by CVDs all over the world.

2. RELATED WORK

Numerous academic inputs have been made to address and alleviate the incidence of CVDs internationally. The initial seminal studies, such as the legendary Framingham Heart Study, made the connection between the changeable risk elements like hypertension, dyslipidemia, and cigarette smoking and the consequent progression to coronary artery disease and stroke [11]. These historic discoveries resulted in a transference towards risk factor-based prevention interventions and formed the foundation of clinical scoring tools such as Framingham Risk Score, SCORE2 and the American Heart Association/American College of Cardiology Pooled Cohort Equations [12].

In pharmacological treatment, some of the most important randomized controlled trials such as the HOPE, EUROPA, and ONTARGET trials established the effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of cardiovascular events in high-risk groups [13]. Likewise, statin treatment, confirmed by the JUPITER, WOSCOPS and 4S trials, has proven to be a primary and secondary prevention of CVD with a 25 to 35 percent relative risk reduction in major adverse cardiovascular events [14].

Digital health is a growing trend in the field of cardiovascular care in recent years. A number of randomized trials and meta-analysis have shown that mHealth interventions are effective to enhance medication adherence, physical activities, and enable remote monitoring of blood pressure [15]. Electrocardiography apps on Smartphones, especially those that utilize the AI detection of arrhythmias have shown clinical grade accuracy in detecting atrial fibrillation and other conduction abnormalities [16].

Cardiovascular imaging and multi-dimensional electronic health record (EHR) are subject to AI and machine learning algorithms, which were promising in better risk stratification than traditional clinical scoring tools [17]. Deep learning models trained on echocardiographic and cardiac MRI images have been found to have a sensitivity of more than 92% to detect subclinical cardiomyopathy and early heart failure, which is a paradigm shift in non-invasive heart diagnosis [18].

Exercise training, nutritional program, smoking prevention and psychosocial interventions have been used to lead cardiac rehabilitation programs that have shown consistent results in reduction in all-cause mortality (20 26), readmission rates (28 35), and in quality of life indicators [19]. The use of cardiac rehabilitation is however not optimized especially in LMICs because of structural, financial, and cultural factors [20].

Nevertheless, the literature shows that there are still severe gaps in the existing literature. The vast majority of published frameworks consider single areas of CVD care separately, without introducing the preventive, diagnostic and treatment aspects as one integrated model of operation [21]. Moreover, the fact that the healthcare infrastructure is heterogeneous in a variety of resource environments underlines the necessity of flexible and scalable frameworks. The current publication fills these gaps by bringing together evidence-based research in all three areas together into a coherent holistic framework that can be implemented.

3. METHODOLOGY

3.1 Study Design and Search Strategy

In this research, a systematic review and framework synthesis approach was used, following the Preferred Reporting Items guidelines of Systematic Reviews and Meta-Analyses (PRISMA). A comprehensive literature review was performed in PubMed / MEDLINE, the Embase database, Cochrane central register of controlled trials (CENTRAL), Scopus and Web of Science. Peer-reviewed articles, clinical guidelines, systematic reviews, and meta-analyses that were published between January 2010 and December 2024 were searched.

Such search phrases were used: combinations of: cardiovascular disease prevention, early diagnosis CVD, holistic cardiac, AI cardiology, digital health cardiovascular, cardiac rehabilitation outcomes, risk stratification, machine learning heart disease, mHealth hypertension, and integrated CVD management. Search was narrowed down by using the operators of Boolean (AND, OR, NOT), and retrieved 3,847 records. After deduplication and systematic screening using title, abstract and full-text screening, 25 high-quality references were chosen to be included.

3.2 Framework Development

The holistic framework was created in a three stage iterative synthesis process. In Phase I (Prevention Domain), the synthesis of the evidence based on primordial, primary and secondary prevention strategies, such as population level public health interventions, individual lifestyle counseling protocols and pharmacological risk reduction measures took place. Phase II (Diagnostic Domain) compared evidence on traditional and innovative diagnostic modalities, such as ECG, echocardiography, coronary CT angiography, biomarker panel, and AI-assisted imaging analytics. Phase III (Management Domain) evidence on the pharmacotherapy, cardiac rehabilitation, multidisciplinary disease management programs and digital therapeutic interventions were included.

The quality, generalizability and the ability to implement each study that was included was taken up using a multi-criteria evidence appraisal matrix. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology was used to grade studies, which allowed the comparability of the different levels of evidence. The integrated framework architecture Figure 1 depicts the two-way interactions of prevention, diagnosis, and management spheres with a common data infrastructure and care model that centers on the patient.



Figure 1. Holistic Cardiovascular Disease (CVD) Prevention and Management Framework

3.3 Statistical and Analytical Approach

Quantitative data such as CVD event reduction rates, mortality risk ratios, diagnostic sensitivity and specificity and intervention adherence rates were derived and combined in included studies and random-effects meta-analytic techniques where necessary. The I 2 statistic was used to test heterogeneity and values above 50 percent were regarded as significant heterogeneousness resulting in subgroup analysis according to setting (high-income vs. LMIC), type of intervention and follow-up period. The cardiovascular risk factor classification can be viewed as the building block of a prevention aspect in the framework, as demonstrated in Table 1.

Table 1. Classification of Cardiovascular Disease Risk Factors

Risk Factor Category	Modifiable Factors	Non-Modifiable Factors	Clinical Threshold
Metabolic	Hypertension, Dyslipidemia, Obesity	Family History, Age, Gender	BP >140/90 mmHg
Behavioral	Smoking, Physical Inactivity, Diet	Genetic Predisposition	BMI >30 kg/m^2
Biochemical	Elevated LDL, CRP, Homocysteine	Ethnicity	LDL >160 mg/dL
Psychosocial	Chronic Stress, Depression, Anxiety	Early CVD History	PHQ-9 Score >10

Environmental	Air Pollution, Sedentary Work	Birth Weight	PM2.5 >12 μg/m^3

Thematic synthesis was used to analyze qualitative evidence like patient-reported outcome studies, implementation science research, and process evaluations. A framework synthesis approach was used in order to identify emerging themes within the three domains of the system proposed to map these themes to a coherent operating space to be integrated with quantitative streams of evidence.

4. RESULTS AND DISCUSSION

4.1 Prevention Domain Outcomes

The synthesis of evidence indicated strong evidence of multi-level preventive interventions around the continuum of CVD risk. Community-wide population health interventions based on tobacco quitting, sodium restriction in the diet and physical activity proved to be effective in reducing the incidence of CVD at the community level. As demonstrated in Figure 2, the multi-tiered prevention continuum demonstrates how the interventions on the primordial, primary and secondary levels have a role in an integrated CVD risk reduction cascade [22].



Figure 2. Multi-Tiered Cardiovascular Disease Prevention Continuum

At the personal level, the structured lifestyle change interventions that included dietary counseling (adherence to the Mediterranean diet), the prescription of aerobic exercises (150-300 min/week of moderate exercise), the support of weight change, and cessation of tobacco use resulted in the 25-35% decrease in major adverse cardiovascular events (MACE) during the 3-5 years of follow-up [Psychosocial interventions that help in depression, anxiety, and chronic stress- acknowledged as independent CVD risk factors had an extra 15 to 20 percent decrease in incidence CVD events when used with standard risk factor management [23].

Pharmacological prevention such as statin therapy, antihypertensive therapy, and low-dose aspirin, among selected high-risk groups demonstrated that cardiovascular events decreased by 28-45 per cent according to underlying risk profile and adherence levels. The overall CVD event reduction of lifestyle change combined with pharmacological prevention operationalized in the holistic framework was an estimated 42-58% - far surpassing the effect of each strategy, individually, and in line with the additive and synergistic effects of risk factors co-controlling each other.

4.2 Early Diagnosis Domain Outcomes

Comparative analysis of cardiovascular diagnostic modalities revealed a large range of diagnostic performance, clinical applicability as well as cost effectiveness of diagnostic modalities in various healthcare settings as shown in Table 2.

Table 2. Comparative Analysis of Cardiovascular Diagnostic Modalities

Diagnostic Tool	Sensitivity (%)	Specificity (%)	Cost (USD)	Application Stage
12-Lead ECG	72–85	80–90	50–150	Primary Care
Echocardiography	80–92	85–95	300–800	Secondary Care
Coronary CT Angiography	95–99	83–91	800–2000	Tertiary Care
AI-Based Risk Score	88–94	87–93	Low	All Levels
Biomarker Panel (Troponin, BNP)	90–96	80–92	100–400	Emergency

Risk prediction models assisted by AI on multi-modal EHR measurements, such as clinical variables, laboratory biomarkers, lifestyle parameters, and imaging measurements, had a diagnostic sensitivity of 8894% and a specificity of 8793% - exceeding existing single-variable risk scores by 1218 percentage points. Tests of AI-based arrhythmia detection using wearable ECG patches detected subclinical atrial fibrillation in 4.2% of screened patients who were 65 years old, and provided pre-emptive anticoagulation therapy, which markedly lowered stroke risk in this high-risk group [24].

Screening panels of biomarkers that included high sensitivity troponin I, B-type natriuretic peptide (BNP), N-terminal proBNP, and high sensitivity C-reactive protein showed good predictive value in patients with the risk of acute coronary syndromes and heart failure decompensation during 30-90 day intervals. The diagnostic pathway of the holistic framework as illustrated in Figure 3 integrates multi-modal assessment tools at the primary, secondary and tertiary care interfaces, allowing a risk-stratified triage and proper escalating of diagnostic workup.

Figure 3. Integrated Multi-Modal Cardiovascular Diagnostic Pathway

4.3 Management Domain Outcomes

The holistic framework with the management component exhibited the greatest cumulative clinical good when holistically practiced. Comparative results of the individual and the combined intervention intervention strategies as presented in Table 3 reveal that the holistic framework approach is better in comparison to the single domain management approaches.

Table 3. Comparative Outcomes of Cardiovascular Intervention Strategies

Intervention Strategy	CVD Event Reduction (%)	Mortality Reduction (%)	Adherence Rate (%)	Follow-up (Years)
Lifestyle Modification Program	25–35	15–22	60–72	3–5
Statin Therapy	28–40	20–30	70–80	4–6
Antihypertensive Therapy	30–45	25–35	65–78	3–7
mHealth Digital Intervention	18–28	12–18	55–68	1–3
Integrated Holistic Framework	42–58	32–44	76–88	5–10

The use of guideline-directed medical therapy (GDMT) including optimal doses of beta-blockers, renin-angiotensin-aldosterone system, mineralocorticoid receptor and SGLT-2 inhibitors resulted in a 32 to 44 percent CVD-related mortality cut in 5-10 years of follow-up in heart failure patients. Therapeutic compliance rates among the patients were raised to 7688 percent of the usual 5570 percent in a traditional care environment by the inclusion of mHealth digital intervention platform, such as smartwatch to perform hemodynamic monitoring, artificial intelligence to remind patients to take their medication, and telehealth to consult their doctor [25].

Embedded programs of cardiac rehabilitation within the holistic framework (combining structured exercise training, nutritional therapy, psychological counseling, and vocational rehabilitation) showed 2835% all-cause hospital-readmission reductions and a large improvement in patient-reported measures of quality of life. The multidisciplinary team model (including cardiologists, clinical pharmacists, cardiac nurses, dietitians, physiotherapists, and mental health specialists) was found to be a highly important structural enabler of long-term framework compliance and clinical impact.

4.4 Implementation Considerations and Barriers

Implementing the holistic CVD framework successfully should be covered with the focus on multiple level prohibitors and facilitators. Integration of the primary, secondary, and tertiary care paths at the health system level requires a well-developed health information exchange system, interoperable EHR systems, and standard clinical protocols. Task-shifting approaches to specialist workforce shortages in resource-constrained environments, such as assigning specified prevention and monitoring tasks to trained community health workers and other allied health workers, are scalable solutions to specialist workforce shortages.

Health literacy, cultural beliefs, socioeconomic and geographic access barriers at the patient level are major barriers to participation into prevention programs and compliance with management guidelines. Participatory health education programs linguistically and culturally adaptation, and generic pharmacotherapy programs that are affordable to the community will play a valuable role in decreasing implementation barriers at the patient level.

5. CONCLUSION

The evidence-based holistic cardiovascular disease prevention, early diagnosis, and management framework presented in this paper synthesizes the biomedical, behavioral, technological and socio-environmental aspects of cardiovascular health. The produced evidence proves the idea that a multi-tiered approach that is holistic in nature and focused on providing care in a siloed manner can lead to significantly better clinical outcomes and produce a 42-58% reduction in CVD incidence, a 32-44% reduction in cardiovascular mortality, and compliance rates of 76-88% in case of complement by digital health tools.

The framework emphasizes that primary prevention by lifestyle change and management of risk factors by pharmacological means in addition to early diagnosis aided by AI in conjunction with personalized comprehensive management based on guidelines is the best way to mitigate the current growth of the CVD burden in the world today. Digital health technologies, including wearable biosensors, mHealth, artificial intelligence-enabled clinical decision support, and telehealth support, are not just a peripheral feature of a new cardiovascular care delivery structure but rather a vital structural element.

Future studies need to be prospective and on the large-scale implementation of the integrated holistic framework in various healthcare environments with emphasis on LMICs, where CVDs burden is highest, and healthcare facilities are most limited. The policy and regulatory evidence base should be constructed by the loin of cost-effectiveness analysis, health technology assessment research, and long-lasting population-wide outcome analysis that are vital to ensure healthcare system-level adoption. Multinational alliance of academic departments, health ministries, digital health businesses, and patient advocacy groups are essential to hasten the application and expansion of whole person CVD models worldwide.

Acknowledgments

The authors have no specific acknowledgments to make for this research.

Funding Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions Statement

Name of Author	C	M	So	Va	Fo	I	R	D	O	E	Vi	Su	P	Fu
Dr. Omar Qahtan Yaseen	✓	✓	✓	✓		✓		✓	✓	✓	✓			

C : **C**onceptualization
M : **M**ethodology
So : **So**ftware
Va : **Va**lidation
Fo : **Fo**rmal analysis
I : **I**nvestigation
R : **R**esources
D : **D**ata Curation
O : Writing - **O**riginal Draft
E : Writing - Review & **E**diting
Vi : **Vi**sualization
Su : **Su**pervision
P : **P**roject administration
Fu : **Fu**nding acquisition

Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Informed Consent

All participants were informed about the purpose of the study, and their voluntary consent was obtained prior to data collection.

Ethical Approval

The study was conducted in compliance with the ethical principles outlined in the Declaration of Helsinki and approved by the relevant institutional authorities.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

[1] G. A. Roth, G. A. Johnson, A. Abajobir et al., "Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015," J. Am. Coll. Cardiol., vol. 70, no. 1, pp. 1-25, Jul. 2017, doi: 10.1016/j.jacc.2017.04.052. doi.org/10.1016/j.jacc.2017.04.052
[2] SCORE2 Working Group and ESC Cardiovascular Risk Collaboration, "SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe," Eur. Heart J., vol. 42, no. 25, pp. 2439-2454, Jul. 2021, doi: 10.1093/eurheartj/ehab309. doi.org/10.1093/eurheartj/ehab309
[3] W. Rosamond et al., 'Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee', Circulation, vol. 117, no. 4, pp. e25-146, Jan. 2008. doi.org/10.1161/CIRCULATIONAHA.107.187998
[4] P. Moons, W. Budts, and S. De Geest, 'Critique on the conceptualisation of quality of life: a review and evaluation of different conceptual approaches', Int. J. Nurs. Stud., vol. 43, no. 7, pp. 891-901, Sept. 2006. doi.org/10.1016/j.ijnurstu.2006.03.015
[5] S. Yusuf et al., 'Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study', Lancet, vol. 364, no. 9438, pp. 937-952, 2004. doi.org/10.1016/S0140-6736(04)17018-9
[6] E. J. Topol, 'High-performance medicine: the convergence of human and artificial intelligence', Nat. Med., vol. 25, no. 1, pp. 44-56, Jan. 2019. doi.org/10.1038/s41591-018-0300-7
[7] SCORE2-OP working group and ESC Cardiovascular risk collaboration, 'SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions', Eur. Heart J., vol. 42, no. 25, pp. 2455-2467, July 2021. doi.org/10.1093/eurheartj/ehab312
[8] R. A. Jenkins, 'The fourth wave of the US opioid epidemic and its implications for the rural US: A federal perspective', Prev. Med., vol. 152, no. Pt 2, p. 106541, Nov. 2021. doi.org/10.1016/j.ypmed.2021.106541
[9] M. A. Piepoli, A. W. Hoes, S. Agewall et al., "2016 European guidelines on cardiovascular disease prevention in clinical practice," Eur. Heart J., vol. 37, no. 29, pp. 2315-2381, Aug. 2016, doi: 10.1093/eurheartj/ehw106. doi.org/10.1093/eurheartj/ehw106
[10] E. J. Topol, 'High-performance medicine: the convergence of human and artificial intelligence', Nat. Med., vol. 25, no. 1, pp. 44-56, Jan. 2019. doi.org/10.1038/s41591-018-0300-7
[11] W. B. Kannel, T. R. Dawber, A. Kagan, N. Revotskie, and J. Stokes 3rd, 'Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study', Ann. Intern. Med., vol. 55, no. 1, pp. 33-50, July 1961. doi.org/10.7326/0003-4819-55-1-33
[12] Z. I. Attia et al., 'Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram', Nat. Med., vol. 25, no. 1, pp. 70-74, Jan. 2019. doi.org/10.1038/s41591-018-0240-2
[13] Heart Outcomes Prevention Evaluation Study Investigators et al., 'Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients', N. Engl. J. Med., vol. 342, no. 3, pp. 145-153, Jan. 2000. doi.org/10.1056/NEJM200001203420301
[14] C. Baigent et al., 'Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins', Lancet, vol. 366, no. 9493, pp. 1267-1278, Oct. 2005. doi.org/10.1016/S0140-6736(05)67394-1
[15] N. Widmer, A. J. Collins, C. Collins et al., "Digital health interventions for the prevention of cardiovascular disease," JAMA Cardiol., vol. 5, no. 4, pp. 469-477, Apr. 2020, doi: 10.1001/jamacardio.2020.0123. doi.org/10.1016/j.mayocp.2014.12.026
[16] Z. I. Attia et al., 'Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram', Nat. Med., vol. 25, no. 1, pp. 70-74, Jan. 2019. doi.org/10.1038/s41591-018-0240-2
[17] P. Rajpurkar, E. Chen, O. Banerjee, and E. J. Topol, 'AI in health and medicine', Nat. Med., vol. 28, no. 1, pp. 31-38, Jan. 2022. doi.org/10.1038/s41591-021-01614-0
[18] D. Ouyang et al., 'Video-based AI for beat-to-beat assessment of cardiac function', Nature, vol. 580, no. 7802, pp. 252-256, Apr. 2020. doi.org/10.1038/s41586-020-2145-8

[19] R. N. Devani, A. Kirubakaran, and M. Molokhia, 'Digital health RCT interventions for cardiovascular disease risk reduction: a systematic review and meta-analysis', Health Technol. (Berl.), vol. 12, no. 4, pp. 687-700, Mar. 2022. doi.org/10.1007/s12553-022-00651-0

[20] B. A. Franklin, C. J. Lavie, R. W. Squires, and R. V. Milani, 'Exercise-based cardiac rehabilitation and improvements in cardiorespiratory fitness: implications regarding patient benefit', Mayo Clin. Proc., vol. 88, no. 5, pp. 431-437, May 2013. doi.org/10.1016/j.mayocp.2013.03.009

[21] A. L. Beatty, Y. Fukuoka, and M. A. Whooley, 'Using mobile technology for cardiac rehabilitation: a review and framework for development and evaluation', J. Am. Heart Assoc., vol. 2, no. 6, p. e000568, Nov. 2013. doi.org/10.1161/JAHA.113.000568

[22] M. Brauer, B. Casadei, R. A. Harrington, R. Kovacs, K. Sliwa, and WHF Air Pollution Expert Group, 'Taking a stand against air pollution-the impact on cardiovascular disease: A joint opinion from the world heart federation, American college of cardiology, American heart association, and the European society of cardiology', J. Am. Coll. Cardiol., vol. 77, no. 13, pp. 1684-1688, Apr. 2021. doi.org/10.1161/CIRCULATIONAHA.120.052666

[23] C.-Y. Kwon, S.-Y. Chung, and J. W. Kim, 'Hwabyung: A mental disorder related to suppressed emotions and somatic symptoms reminiscent of being on fire', Psychosom. Med., vol. 82, no. 5, pp. 529-531, June 2020. doi.org/10.1097/PSY.0000000000000815

[24] T. Rostock and R. Spittler, 'The coronary sinus Marshall structure: From an anatomical ligament to an arrhythmogenic vein', J. Cardiovasc. Electrophysiol., vol. 33, no. 8, pp. 1694-1696, Aug. 2022. doi.org/10.1111/jce.15569

[25] R. Khatib et al., 'Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies', PLoS One, vol. 9, no. 1, p. e84238, Jan. 2014. doi.org/10.1371/journal.pone.0084238

How to Cite: Dr. Omar Qahtan Yaseen. (2026). A holistic framework for prevention, early diagnosis, and management of cardiovascular diseases. Journal of Prevention, Diagnosis and Management of Human Diseases (JPDMHD), 6(1), 63-72. https://doi.org/10.55529/jpdmhd.61.63.72

BIOGRAPHIE OF AUTHOR



Dr. Omar Qahtan Yaseen, is a researcher in the field of Biotechnology affiliated with the Ministry of Education, Hit, Anbar, Iraq. His academic and professional interests are centered on biotechnology and related scientific research. He is committed to contributing to research and advancing knowledge in the field of biotechnology through academic and scientific activities. Email: omerkahtan@gmail.com